Ondansetron STADA Filmuhúðuð tafla 4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ondansetron stada filmuhúðuð tafla 4 mg

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Oxaliplatin Actavis Innrennslisþykkni, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oxaliplatin actavis innrennslisþykkni, lausn 5 mg/ml

actavis group ptc ehf. - oxaliplatinum inn - innrennslisþykkni, lausn - 5 mg/ml

Zofran Filmuhúðuð tafla 4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 4 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Zofran Filmuhúðuð tafla 8 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 8 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Zofran Mixtúra, lausn 0,8 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran mixtúra, lausn 0,8 mg/ml

sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml

Tibsovo Evrópusambandið - íslenska - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Herwenda Evrópusambandið - íslenska - EMA (European Medicines Agency)

herwenda

sandoz gmbh - trastuzúmab - breast neoplasms; stomach neoplasms - Æxlishemjandi lyf - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Cimzia Evrópusambandið - íslenska - EMA (European Medicines Agency)

cimzia

ucb pharma sa - certolizumab pegol - crohn disease - Ónæmisbælandi lyf - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. Þegar hægt er að gefa eitt og sér í málið óþol stendur eða þegar áframhaldandi meðferð með stendur er óviðeigandi. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.